Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors

NCT05082701 is registered in ClinicalTrials.gov with Strata Oncology as lead sponsor.

NCT NCT05082701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05082701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sentinel™ Trial: A Prospective Study Evaluating the Performance and Clinical Benefit of Personalized ctDNA-based MRD Testing to Detect Recurrence and Monitor Treatment Response in Patients With Solid Tumors
Lead sponsor
Strata Oncology
Phase
Observational
Overall status
Terminated
Start date
December 3, 2021
Completion date
February 22, 2024
Enrollment
295 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer